Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor

This publication has 46 references indexed in Scilit:

• LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
  Annals of Oncology, 2023
• Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial
  ESMO Open, 2023
• Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience
  Clinical Genitourinary Cancer, 2023
• Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
  Clinical Genitourinary Cancer, 2022
• Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
  Clinical Genitourinary Cancer, 2022
• Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
  Clinical Genitourinary Cancer, 2022
• Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
  Clinical Genitourinary Cancer, 2021
• Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
  Cancer, 2019
• Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy
  Clinical Genitourinary Cancer, 2018
• World Medical Association Declaration of Helsinki
  JAMA, 2013